In the summer of 2024, a baby named KJ was born with a rare disease with a 50% mortality rate. Six months later, he became the first patient to receive personalized gene editing therapy. He is now healthy and thriving. Dr. Jeff Coller, who directs the RNA Innovation Center at Johns Hopkins University, says KJ’s treatment could be the most important medical story of the decade. Today, Dr. Coller explains the ground-breaking science behind KJ’s treatment, and what it will take to bring it mainstream.

Learn more about your ad choices. Visit podcastchoices.com/adchoices